IMF Videos Search Content For Healthcare Professional (70) Healthcare Provider (70) Series - Any - About the IMF (2) ASCO/EHA (70) ASH (102) Ask Dr. Durie (150) Black Swan Research Initiative (7) Community Workshops (5) Emerging Therapies (18) Facebook Live (21) Health Equity (14) IMF History (3) IMWG (12) Inspirational (15) Living Well with Myeloma (33) Myeloma in a Minute (20) Myeloma Made Simple (15) Myeloma University (12) NLB Webcasts (1) Patient & Family Webinar (11) Q&A (21) Recent News and Developments (5) Treatments (3) Trending Searches in Myeloma (4) Topics Clinical Trials (49) Financial Considerations (1) Frontline Therapy (16) Health Equity (2) Lab & Imaging Tests (1) Mental & Emotional Health (1) Myeloma in the News (1) Public Policy & Advocacy (1) Recorded Webinars (2) Relapse/Refractory Myeloma (31) Research Updates (51) Symptom Management (4) Myeloma Stage Early Relapse (1–3 Lines of Therapy) (16) High-Risk Myeloma (14) High-risk Smoldering Myeloma (9) Late Relapse (4–6 Lines of Therapy) (29) MGUS (5) Newly Diagnosed (Pre-Treatment or First Treatment) (20) Smoldering Myeloma (7) Types of Therapy Immunomodulatory drugs (IMiDs) (22) Immunotherapies (CAR T; BiTE, etc.) (30) Monoclonal antibodies (20) Proteasome inhibitors (20) Stem cell transplant (10) Steroids (17) Supportive Care (8) Year Published 2026 (1) 2025 (14) 2024 (17) 2023 (17) 2022 (1) 2021 (3) 2020 (3) 2019 (2) 2018 (2) 2017 (5) 2015 (5) Trusted Voices Dr. Joseph Mikhael (2) Dr. María-Victoria Mateos (1) Dr. S. Vincent Rajkumar (1) Sort Newest firstOldest firstA -> ZZ -> ARelevance Efficacy, Safety, and Determination of ABBV-383, a BCMA Bispecific Antibody, in Patients with Relapsed Refractory Multiple Myeloma June 21, 2024 ASCO/EHA LINKER-MM1: Linvoseltamab for RR Multiple Myeloma Deep, Durable Responses at 14-Month Follow-Up June 20, 2024 ASCO/EHA Idecabtagene Vicleucel for High-Risk Early Relapse Multiple Myeloma - KarMMa-2 Study June 19, 2024 ASCO/EHA IMROZ: Isa-VRd vs VRd for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma June 17, 2024 ASCO/EHA DREAMM-8 Study: Belantamab mafodotin plus pomalidomide and dexamethasone shows improved outcomes in relapsed/refractory multiple myeloma June 14, 2024 ASCO/EHA Isatuximab Plus Len/Dex/Bortezomib vs IsaRd in Newly Diagnosed Transplant Ineligible Multiple Myeloma June 12, 2024 ASCO/EHA Improved Depth of Response and MRD Negativity with DARA + VRd in Transplant-Eligible NDMM: PERSEUS Trial Results June 10, 2024 ASCO/EHA Cevostamab Shows Promise in Hard-to-Treat Multiple Myeloma June 6, 2024 ASCO/EHA Phase 3, open-label, randomized trial comparing safety and efficacy of belamaf to Pd in RRMM: DREAMM-3 study July 10, 2023 ASCO/EHA CARTITUDE-1: Final results of Ciltacabtagene Autoleucel in heavily pretreated relapsed/refractory multiple myeloma July 7, 2023 ASCO/EHA Pivotal phase 2 MonumenTAL-1 results of talquetamab, a GPRC5DxCD3 bispecific antibody, for relapsed refractory multiple myeloma July 3, 2023 ASCO/EHA Quadruplet Induction Therapy, ASCT and MRD-modulated Consolidation and Treatment Cessation in Newly Diagnosed Multiple Myeloma July 1, 2023 ASCO/EHA Load More
